Herein, we describe our studies on the synthesis of 1α,25-dihydroxyvitamin D 3 analogs possessing a benzene ring replacing the natural 5-membered D-ring by the Wittig-Horner and dienyne approaches. A key feature is the synthesis of a Cr(CO) 3 -complexed previtamin D derivative that enables the construction of vitamin D analogs with aromatic D-ring through a thermal [1,7]-H sigmatropic shift. This study establishes the basis for the design of new vitamin D analogs containing aromatic D-ring, complexed or uncomplexed to Cr(CO) 3 type moieties for specific molecular recognition and drug research and development.
INTRODUCTION
1α,25-Dihydroxyvitamin D 3 [1, 1,25D, calcitriol, Figure 1 ], the most potent steroid hormone known and the active metabolite of the seco-steroid vitamin D 3 , interacts with the vitamin D nuclear receptor (VDR), a member of the nuclear receptor superfamily, to dimerize with the retinoid X receptor (RXR). The heterodimer binds to the vitamin D response elements (VDREs) in target gene promoters and recruit coactivator proteins to induce a cascade of events including control of mineral homeostasis and various important cellular processes such as differentiation, anti-proliferation, growth, angiogenesis, apoptosis, and immunomodulation (Norman et al. 1979 , Evans et al. 1988 , Kliewer et al. 1992 , Bouillon et al. 1995 , Feldman et al. 2011 . Recently, it was discovered that 1,25D activates more than 229 genes associated with several diseases, including arthritis, diabetes and cancer, suggesting that this hormone might have an even broader range of biological functions than originally thought (Lincoln et al. 2010 ) 1,25D itself has clinical applications, but the pharmacological doses required for treatment of cancer induce strong, undesired hypercalcemia (Plum et al. 2010 , Feldman et al. 1997 . Structure-function studies of numerous 1,25D analogs have shown that the undesired calcemic effects can be reduced during cell-differentiating activities, but the mechanism of this selectivity has not yet been unraveled (Feldman et al. 2011 , Glebocka et al. 2012 . Increasing synthetic efforts have been directed at the development of non-calcemic analogs of the natural hormone 1,25D for treatment of specific disorders, but only a few have found clinical applications. Among these, calcipotriol (2, Figure 1 ) and OCT (3), two analogs with structural modifications at the side chain, are being successfully used for treatment of psoriasis (Feldman et al. 1997) . A few structural features that reduce the calcemic activity include: a) unsaturations at the side chain or D-ring (Verlinden et al. 2000) , b) the lack of the 19-methylene group (Kensler et al. 2000) , c) 14-epi-configuration (Verlinden et al. 2000 , Ma et al. 2013 ), d) 3-epi-configuration (Molnar et al. 2011) , e) short non-hydroxylated side chains (Plum et al. 2004 ), f) CD-carboranic mimics (Yamada et al. 2014 ) and g) o-carboranic side chains (Otero et al. 2016) . Nonsecosteroidal vitamin D receptor modulators that reduce calcemic effects have also been reported (Eduardo-Canosa et al. 2010) .
Our continued interest in the synthesis of 1,25D analogs with selective properties as potential drugs for treatment of cancer and/or psoriasis led us to study the synthesis of aromatic compounds 4a and 4b (Figure 1 ) as models, which bear a benzene ring replacing the natural 5-membered D-ring. Preliminary studies to build the triene system of 4 utilizing the Wittig-Horner coupling approach (route A) (Lythgoe 1980) between phosphineoxide-lithium anion 5 and ketone 6 resulted in the recovery of starting ketone presumably through the corresponding enolate (Figure 2 ). Attempts to synthesize 4b through the dienyne approach (route B) (Castedo et al. 1986 ) were hampered by difficulties to accomplish the sigmatropic [1, 7] -H shift on the previtamin 7, presumably due to crossconjugation of the triene system with the aromatic ring. Here we describe our efforts to synthesize 4a through route A and 4b through route B, from ketone-Cr(CO) 3 complex 9. Complexation with Cr(CO) 6 was envisioned as a way to reduce conjugation of the aromatic ring with either the carbonyl group in tetralone 6 or the triene system in 7.
MATERIALS AND METHODS

GENERAL MATERIALS AND METHODS
Reagents were purchased from Aldrich Chemical (www.sigma-aldrich.com) or Acros Organics (www.acros.com) and used without further purification. All reactions involving oxygen or moisture sensitive compounds were carried out under dry argon atmosphere using oven-dried or flame-dried glassware and standard syring/septa tecniques. All dry solvents were distilled under argon immediately prior to use: Tetrahydrofuran (THF), Et 2 O and n-Bu 2 O were distilled from Na/ benzophenone. CH 2 Cl 2 and Ac 2 O were distilled from P 2 O 5 . Hexanes, n-heptane, diisopropilamine (i-PrNH 2 ) and triethylamine (Et 3 N) were distilled from CaH 2 . MeOH was distilled from Mg/I 2 . DMSO was distilled from CaH 2 and stored over activated 4 Å molecular sieves. Solutions of n-butyllithium -(1,2,3,4-tetrahydronaftalen-1-ol)] chromium(0) (11). Alcohol 10 (0.100 g, 0.67 mmol, 1.5 equiv) and Cr(CO) 6 (0.222 g, 1.01 mmol, 1 equiv) were dissolved in a mixture of n-Bu 2 O/n-heptane (8 mL, 1:1). The solution was deoxygenated. A stream of argon was passed through the solution. Dry THF (0.4 mL) was added. The reaction mixture was heated at reflux in the dark for 54 h. The mixture was allowed to reach 23 ºC and filtered through a pad of celite. The solids were washed with CH 2 Cl 2 and the combined solution was concentrated in vacuo. The residue was purified by flash chromatography (50% CH 2 Cl 2 /hexanes) to give 11 (Schmalz et al. 1992 
Tr i c a r b o n y l -{ η 6 -[ 3 , 4 -d i h y d r o -1 -((trifluoromethanesulfonyl)oxy)naftalen]} chromium(0) (14).
D-RING-AROMATIC VITAMIN D COMPOUNDS 1039
A solution of lithium diisopropylamide was prepared by slowly addition of a solution of n-BuLi in hexanes (0.42 mL, 0.92 mmol, 2.2M, 1.3 equiv) to a-78 ºC cooled neat i-Pr 2 NH (0.14 mL, 1.01 mmol, 1.4 equiv). The bath was removed and the white slurry was stirred at 23 ºC for 15 min. The suspension was cooled to -78 ºC and dry THF (2.5 mL) was added. After 15 min, a solution of ketone 9 (0.200 g, 0.71 mmol, 1 equiv) in dry THF (2 mL) was added dropwise. The reaction mixture was stirred at -78 ºC for 45 min and a solution of N,N-(5-chloropyridin-2-yl)-bistriflimide (0.444 g, 1.13 mmol, 1.6 equiv) in dry THF (1.5 mL) was added via cannula. The mixture was allowed to reach 23 ºC. The reaction was quenched by the addition of H 2 O (10 mL). The mixture was extracted with EtOAc (3x10 mL). The combined organic layers were dried, filtered and concentrated. 
, 5 -b i s -( t e r t -b u t y l d i m e t h y l s i l y l o x y ) -2 -methyl-cyclohex-1-en-1-yl]ethynyl)-naftalen} chromium(0) (16).
Compound 15 (0.120 g, 0.31 mmol, 1.3 equiv), PdCl 2 (PPh 3 ) 2 (8 mg, 0.011 mmol, 5 mol%) and CuI (2 mg, 0.011 mmol, 5 mol%) were successively added to a solution of 14 (0.100 g, 0.24 mmol, 1 equiv) in dry Et 3 N (3 mL). The reaction mixture was heated at 60 °C for 2 h. The mixture was allowed to reach 23 ºC and then filtered through a pad of celite. The solids were washed with CH 2 Cl 2 (3x5 mL) and the combined solution was washed with a sat NH 4 Cl (20 mL). The aqueous layer was extracted with CH 2 Cl 2 (3x25 mL). The combined organic extracts were dried, filtered and concentrated in vacuo. The residue was purified by flash chromatography ( were successively added to a solution of enyne 16 (0.100 g, 0.16 mmol, 1 equiv) in dry hexanes (27 mL). The system was purged three times with argon and two times with hydrogen. The reaction mixture was stirred under hydrogen at balloon pressure for 1 h and then filtered through a pad of celite. The solids were washed with hexanes and the combined solution was concentrated in vacuo. 
RESULTS AND DISCUSSION
Complex 9 was prepared according to Schmalz's procedure (Figure 3 ) (Schmalz et al. 1992) . Reduction of ketone 6 with sodium borohydride in methanol provided alcohol 10 in 98% yield.
Heating at reflux a mixture of 10 and chromium hexacarbonyl in n-heptane/n-Bu 2 O/THF (10:10:1) gave the diastereomeric alcohols 11 in 39% yield, which upon oxidation with Ac 2 O and DMSO produced the desired Cr(CO) 3 -complex 9 in 84% yield. Wittig-Horner coupling between ketone 9 and phosphine oxide anion 5 in THF furnished a mixture of four diastereomers (12+13), which could be separated by HPLC [12 (two diastereomers 0.7% + 5.5%); 13 (two distereomers 0.5 + 1.7%)] together with recovered starting ketone 9 (64%). Each pair of diastereomers could not be distinguished by 1 H NMR (500 MHz). The H7 and H15 of 12 appear deshielded with respect to those corresponding to 13 (steroid numbering is used for discussion).
The structure 12 was established by 1 H NMR nOe analysis.
Though the Cr(CO) 3 -complexation reduces conjugation of the aromatic unit with the carbonyl group, the yield on Wittig-Horner reaction products is still too low to considerer this approach of preparative value. This result led us to examine the dienyne approach (route B, Figure 2 ) as an alternative pathway to the target compound 4b (Figure 4) . Treatment of ketone 9 with LDA followed trapping of the resulting enolate with 2-[N,N-bis(trifluoromethylsulfonyl)-amino]-5-chloropyridine afforded vinyl triflate 14 (73%), which upon Sonogashira coupling (Sonogashira et al. 1998 ) with enyne 15 in the presence catalytic amounts of CuI and PdCl 2 (PPh 3 ) 2 provided the dienyne 16 (68%). Semihydrogenation of the triple bond in the presence of Lindlar catalyst and quinoline in hexanes gave the previtamin D 17 in 35% yield. Finally, thermal sigmatropic [1, 7] -H shift on 17 in refluxing isooctane followed by Cr(CO) 3 -decomplexation with ammonium cerium(IV) nitrate in methanol gave a 1:0.7 mixture of the target protected vitamin 4b and the corresponding previtamin 7 in 68% yield. The formation of the previtamin 7 can be rationalized 
